文献速递肝病

肝硬化腹水患者的长期白蛋白治疗

Long-term albumin treatment in patients with cirrhosis and ascites.
PubMed 文献 · J Hepatol · 2022-01-01

本文综述长期人血白蛋白治疗肝硬化腹水的现有数据。ANSWER与MACHT研究表明,在足够剂量和疗程下长期白蛋白治疗可有效、安全并可能改变疾病进程。仍需进一步临床研究和随机试验确认临床获益,并明确目标人群、应答生物标志物、最佳剂量与输注频率、停药规则及成本效益。

要点

  • ANSWER与MACHT研究提示长期白蛋白治疗可有效、安全并可能改变疾病进程。
  • 疗效前提是足够剂量和足够时间以恢复循环白蛋白的生理水平与功能。
  • 需进一步研究明确目标人群、应答生物标志物、最佳剂量与频率、停药规则及成本效益。

核心结论

  • ANSWER与MACHT研究结果表明,长期白蛋白治疗可有效、安全并可能改变疾病进程,前提是给予足够剂量和足够时间以恢复循环分子的生理水平与功能。
  • 仍需进一步临床研究和随机试验确认长期白蛋白治疗的临床获益。

研究设计与样本

  • 本文为综述,批判性分析长期白蛋白治疗的现有数据,聚焦研究间差异、争议问题与未来展望。

主要发现

  • 长期白蛋白给药代表与急性或短期使用白蛋白完全不同的治疗视角。
  • 失代偿期肝硬化患者循环白蛋白的生理水平与功能至少部分受损。
  • 长期白蛋白治疗可有效、安全并可能改变疾病进程,前提是剂量和疗程足以恢复循环分子的生理水平与功能。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需进一步临床研究和随机试验确认长期白蛋白治疗的临床获益。
  • 需进一步研究确定精确的目标人群、应答生物标志物、白蛋白输注的最佳剂量与频率、停药规则以及在不同医疗体系中的成本效益。
  • 在部分医疗体系中,定期静脉输注相关的后勤问题和成本可能严重限制这一创新方法在临床实践中的实施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although proposed for the first time several decades ago, the possibility that long-term human albumin could be effective for the treatment of patients with cirrhosis and ascites has become a topic of scientific and clinical discussion in the last decade. Long-term albumin administration represents a completely different treatment perspective compared to acute or short-term uses of albumin. Results from the ANSWER and the MACHT studies indicate that long-term albumin treatment can be effective, safe and able to modify the course of the disease provided that albumin is given at a sufficient dose and for a sufficient time to restore physiological levels and functions of the circulating molecule, which are compromised, at least partially, in patients with decompensated cirrhosis. Further clinical studies and randomised trials are warranted to confirm the clinical benefits of long-term albumin therapy. Important areas for further research include determining the precise target population, the biomarkers of response, the optimal dose and frequency of albumin infusions, the stopping rules, and the cost-effectiveness of treatment in different healthcare systems across the world, particularly in those where the logistical issues and costs related to the periodic intravenous infusions may represent an important limitation to the implementation of this innovative approach in clinical practice. In this review, we will critically analyse the available data on long-term albumin treatment, focusing on the differences that exist between studies, the controversial issues and the future perspectives.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Caraceni P, O'Brien A, Gines P, et al. Long-term albumin treatment in patients with cirrhosis and ascites. J Hepatol. 2022. PMID: 35589252. doi:10.1016/j.jhep.2022.03.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。